JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 December 2006

J Clin Pathol. Published Online First: 5 May 2006. doi:10.1136/jcp.2005.035451
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow web only tables
Right arrow All Versions of this Article:
jcp.2005.035451v1
59/12/1254    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Braakhuis, B. J.M.
Right arrow Articles by Brakenhoff, R. H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Braakhuis, B. J.M.
Right arrow Articles by Brakenhoff, R. H
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Head and Neck Cancer

Molecular Pathology

Expression profiling and prediction of distant metastases in head and neck squamous cell carcinoma

Boudewijn J.M. Braakhuis 1*, Asaf Senft 1, Remco de Bree 1, Janny de Vries 1, Bauke Ylstra 1, Jacqueline Cloos 1, Dirk J Kuik 1, C. Rene Leemans 1 and Ruud H Brakenhoff 1

1 VU University Medical Center, Netherlands

* To whom correspondence should be addressed. E-mail: bjm.braakhuis{at}vumc.nl.

Accepted 5 February 2006


*   Abstract

Background: For breast and prostate cancer, a gene expression signature of the tumor is associated with the development of distant metastases. Regarding head and neck squamous cell carcinoma (HNSCC) the only known risk factor is the presence of three or more tumor-positive lymph nodes; approximately 50% of these patients develop distant metastases.

Aims: To evaluate whether a HNSCC gene expression signature is able to discriminate the patients with and without distant metastases. To validate the platform or chosen analysis, we included normal mucosa of the head and neck as control.

Methods: HNSCC patients in both groups had more than three tumor-positive lymph nodes and did not differ with respect to other risk factors. Statistical analysis was performed using the Student's T-test, as well as Statistical Analysis of Micro-arrays (SAM) to assess the false discovery rate for each gene. These analyses were supplemented with a newly developed method that computes deviations from Gaussian order statistics (DEGOS).

Results: In total, 2,963 genes were differently expressed between HNSCC and normal mucosa (T-test; P<0.01). More rigorous statistical analysis with SAM confirmed the differential expression of a majority of these genes. The comparison of HNSCC with and without metastases revealed 150 differently expressed genes (T-test; P<0.01), none of which, however, could be confirmed with SAM or DEGOS.

Conclusions: No evidence for a metastasis signature is found, and gene expression profiling of HNSCC has seemingly no value in determining the risk to develop distant metastases. The absence of such a signature can be understood when it is realized that for HNSCC in contrast to breast cancer, the lymph nodes are a necessary in-between station for hematogenous spread.

Key Words: expression profiling, head and neck cancer, metastasis, micro-array







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.